StockNews.AI
CYBN
StockNews.AI
222 days

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

1. Cybin's CEO will appear at the 2025 Investor Healthcare Summit. 2. The event highlights Cybin's commitment to mental healthcare innovation. 3. Cybin develops treatments for Major Depressive Disorder and Generalized Anxiety Disorder. 4. The company is advancing next-generation treatment options with strong proof-of-concept data.

3m saved
Insight
Article

FAQ

Why Bullish?

CEO participation in key investor events often boosts investor confidence and sentiment.

How important is it?

The article promotes awareness of Cybin’s leadership and strategic direction during a pivotal time.

Why Long Term?

Following positive developments can enhance long-term investor outlook on CYBN's growth potential.

Related Companies

CYBNMDMACOMP
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat will be webcast live on Monday, January 13, 2025, at 11:30 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of Major Depressive Disorder and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule in a Phase 2 study for Generalized Anxiety Disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Related News